{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:38:29Z","timestamp":1786736309446,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Family Med Prim Care"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jfmpc.jfmpc_892_19","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T07:18:31Z","timestamp":1580195911000},"page":"402","source":"Crossref","is-referenced-by-count":1,"title":["Prescription patterns of antipsychotics in the management of  first episode psychosis at three psychiatric hospitals in Khartoum, 2018: A descriptive cross-sectional study"],"prefix":"10.4103","volume":"9","author":[{"given":"BashirA","family":"Yousef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MalazM A","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2249-4863.276803-1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2008.04.027","article-title":"Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia","author":"Kelly","year":"2008","journal-title":"Schizophr Res"},{"key":"key-10.4103\/2249-4863.276803-2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.schres.2008.09.026","article-title":"Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia","author":"Sacco","year":"2009","journal-title":"Schizophr Res"},{"key":"key-10.4103\/2249-4863.276803-3","first-page":"240","article-title":"Letters to the editors high-dose ziprasidone monotherapy in bipolar i disorder patients with depressed or mixed episodes clinical experience with carbamazepine overdose relationship between serum concentration and neurological severity","author":"Con-","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"key-10.4103\/2249-4863.276803-4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 Update","author":"Moore","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World federation of societies of biological psychiatry (WFSBP)-Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia","author":"Falkai","year":"2005","journal-title":"World J Biol Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-6","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/psychiatry.IndianJPsychiatry_556_18","article-title":"Clinical practice guidelines for the management of schizophrenia in children and adolescents","author":"Grover","year":"2019","journal-title":"Indian J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5545","issn-type":"print"},{"key":"key-10.4103\/2249-4863.276803-8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","article-title":"Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","author":"Singh","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/2249-4863.276803-9","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2147\/NDT.S208061","article-title":"Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: A critical review","author":"Xu","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"key-10.4103\/2249-4863.276803-10","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1345\/aph.1L155","article-title":"Antipsychotic medication utilization trends among Texas veterans: 1997-2002","author":"Yang","year":"2008","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2249-4863.276803-11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009","author":"Gallego","year":"2012","journal-title":"Schizophr Res"},{"key":"key-10.4103\/2249-4863.276803-12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.60.6.565","article-title":"Sex differences in the risk of schizophrenia: Evidence from meta-analysis","author":"Aleman","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00127-014-0989-7","article-title":"Traditional and religious healers in the pathway to care for people with mental disorders in Africa : A systematic review and meta- analysis","author":"Burns","year":"2015","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"key-10.4103\/2249-4863.276803-14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","article-title":"Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis","author":"Perkins","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fpsyt.2019.00067","article-title":"Predictive factors of treatment resistance in first episode of psychosis : A systematic review","author":"Bozzatello","year":"2019","journal-title":"Front Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-16","first-page":"341","article-title":"Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication","author":"De","year":"2003","journal-title":"Schizophr Bull"},{"key":"key-10.4103\/2249-4863.276803-17","doi-asserted-by":"crossref","first-page":"g1173","DOI":"10.1136\/bmj.g1173","article-title":"Management of psychosis and schizophrenia in adults: Summary of updated NICE guidance","author":"Kuipers","year":"2014","journal-title":"BMJ"},{"key":"key-10.4103\/2249-4863.276803-18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"key":"key-10.4103\/2249-4863.276803-20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2006.06.021","article-title":"Olanzapine and haloperidol in first episode psychosis: Two-year data","author":"Green","year":"2006","journal-title":"Schizophr Res"},{"key":"key-10.4103\/2249-4863.276803-21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial early psychosis global working group","author":"Schooler","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-22","first-page":"714","article-title":"Benzodiazepines in the treatment of schizophrenia","author":"Wolkowitz","year":"1991","journal-title":"A Review and re-appraisal Am J Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-23","first-page":"166S","article-title":"Benzodiazepines in schizophrenia","author":"Stimmel","year":"1996","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/2249-4863.276803-24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/YIC.0000000000000254","article-title":"Add-on benzodiazepines for psychosis-induced aggression","author":"Baranchik","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"key-10.4103\/2249-4863.276803-25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/schbul\/4.1.3","article-title":"Therapeutic antagonism between anticholinergics and neuroleptics: Possible involvement of cholinergic mechanisms in schizophrenia","author":"Singh","year":"1978","journal-title":"Schizophr Bull"},{"key":"key-10.4103\/2249-4863.276803-26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002512-199914030-00005","article-title":"Epidemiology of adverse drug reactions in the elderly by drug class","author":"Beyth","year":"1999","journal-title":"Drugs Aging"},{"key":"key-10.4103\/2249-4863.276803-27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.2000.00132.x","article-title":"Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine","author":"Fattinger","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/2249-4863.276803-28","first-page":"3","article-title":"Overview of partial compliance","author":"Marder","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"key-10.4103\/2249-4863.276803-29","first-page":"295","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review","author":"De","year":"2008","journal-title":"Schizophr Res"},{"key":"key-10.4103\/2249-4863.276803-30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0006-3223(03)00170-7","article-title":"Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients","author":"Dolder","year":"2003","journal-title":"Biol Psychiatry"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:40:14Z","timestamp":1786732814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_892_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["276803"],"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_892_19","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}